A Phase II Study of Oral EGFR Tyrosine Kinase Inhibitor OSI-774 (NSC-718781) in Patients With Malignant Pleural Mesothelioma
Latest Information Update: 21 Apr 2023
At a glance
- Drugs Erlotinib (Primary)
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- 28 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Mar 2008 Status changed from completed to in progress, as reported by ClinicalTrials.gov.
- 26 Jun 2007 Status changed from in progress to completed.